Teacher Insights: How Digital Technology Helps in Growth and Access to Quality Education  |  Management lessons: How Brands Use CARE to Stay on Top in Instagram  |  Hobbies &Trends: At Full Throttle  |  Finance: Bitcoin Mobile Apps Vulnerable to Security Threats: Guan-Hua Tu, MSU  |  International Edu News: Use plants' ability to tell the time to make food production more sustainable  |  International Edu News: Scientists develop new class of cancer drug with potential to treat leukaemia  |  International Edu News: Loan applications processed around midday more likely to be rejected  |  International Edu News: Researchers find climate change impacts plankton – a key marine food source  |  International Edu News: Nature must be a partner, not just a provider of services – Oxford report  |  National Edu News: Approval to MoU between India and UK on Global Innovation Partnership  |  National Edu News: Transfer of CSIR-CMERI technologies to three MSMEs  |  Parent Interventions: Child Learning Programs: How to Find the Right One for You  |  Rajagiri Round Table: Fitness Challenge for the Nation  |  Education Information: West Bengal Scholarship 2021  |  Education Information: What is PMEGP Scheme? How can you get it?  |  
April 26, 2021 Monday 08:39:24 PM IST

‘Virafin’ from Zydus Gets Emergency Nod For Treating Moderate COVID-19

Drug Controller General Of India (DCGI) gave a restricted emergency use approval to Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, resulted in their faster recovery. For the development of Virafin, Zydus appreciated the support provided by  DBT-BIRAC COVID 19 Research Consoritum through NBM, for conducting the Phase II human clinical trial studies. The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels. Speaking on this achievement Dr Renu Swarup, Secretary, DBT and Chairperson, BIRAC said, ‘’The government has been committed to providing all possible facilitation to our industries to work towards mitigation strategies and interventions against COVID-19 pandemic. The emergency nod provided to Virafin is another milestone that is a boon for the medical facility providers. I highly appreciate the efforts put in for this achievement.”

Phase III clinical trial studies reported that a larger proportion of patients when administered subcutaneously with Virafin turned out to be RT-PCR negative by day 7, apart from faster recovery as compared to other anti-viral agents.

Comments